BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to PaCa-44 cell line is 229
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NANOG | 20857 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | PaCa-44 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.5461 | 34168259 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | PaCa-44 | NA | Prolonged exposure to simulated microgravity followed by qRT-PCR | NA | 0.48 | 0.5461 | 35391557 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | PaCa-44 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.5695 | 34168259 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | PaCa-44 | NA | Prolonged exposure to simulated microgravity followed by qRT-PCR | NA | 0.48 | 0.5695 | 35391557 |
| HNRNPAB | 5034 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0032 | 34168259 |
| LDHA | 6535 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0053 | 34168259 |
| VDAC2 | 12672 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.36 | 0.0011 | 34168259 |
| HDHA | NA | HTM/LTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0011 | 34168259 |
| HNRNPAB | 5034 | HTM/LTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics and Western Blotting | Down | 0.36 | 0.0032 | 34168259 |
| LDHA | 6535 | HTM/LTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics and Western Blotting | Down | 0.36 | 0.0053 | 34168259 |
| VDAC2 | 12672 | HTM/LTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0011 | 34168259 |
| ALDH1A3 | 409 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | PaCa-44 | NA | Prolonged exposure to simulated microgravity followed by qRT-PCR | NA | 0.2 | 0.0201 | 35391557 |
| CCNB1 | 1579 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by qPCR | NA | 0.2 | 0.0053 | 34168259 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | PaCa-44 | NA | Prolonged exposure to simulated microgravity followed by qRT-PCR | NA | 0.2 | 0.211 | 35391557 |
| FZD2 | 4040 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by qPCR | NA | 0.2 | 0.0021 | 34168259 |
| ITGA3 | 6139 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | PaCa-44 | NA | Prolonged exposure to simulated microgravity followed by qRT-PCR | NA | 0.2 | 0.0032 | 35391557 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | PaCa-44 | NA | Prolonged exposure to simulated microgravity followed by qRT-PCR | NA | 0.2 | 0.6448 | 35391557 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | PaCa-44 | NA | SFA followed by qPCR | NA | 0.2 | 0.6448 | 34168259 |
| ROHA | 667 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | PaCa-44 | NA | Prolonged exposure to simulated microgravity followed by qRT-PCR | NA | 0.2 | 0.0011 | 35391557 |
| S100A4 | 10494 | LTM | Pancreatic Cancer | Ductal Adenocarcinoma | PaCa-44 | NA | Prolonged exposure to simulated microgravity followed by qRT-PCR | NA | 0.2 | 0.0074 | 35391557 |
| ACAA1 | 82 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| ACOT13 | 20999 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| ACTN1 | 163 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| AK2 | 362 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| ALDH1A1 | 402 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.684 | 34168259 |
| ALDH1A3 | 409 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0201 | 34168259 |
| ALDH3A1 | 405 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 34168259 |
| ALDH3A2 | 403 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| ANXA1 | 533 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 34168259 |
| ANXA4 | 542 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| AP3D1 | 568 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| APMAP | 13238 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| APRT | 626 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| ARCN1 | 649 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| ARF4 | 655 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| ARHGDIB | 679 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| ASAH1 | 735 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| ATIC | 794 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| ATP5F1A | 823 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| ATP5F1B | 830 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| ATP5F1C | 833 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| ATP5PO | 850 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| CALM3 | 1449 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| CAT | 1516 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| CAV1 | 1527 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0117 | 34168259 |
| CDC37 | 1735 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| CDC42 | 1736 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| CEACAM1 | 1814 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0064 | 34168259 |
| CFAP57 | 26485 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| CFL1 | 1874 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| CLTA | 2090 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| CLTC | 2092 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| CMPK1 | 18170 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| COPB2 | 2232 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| COPG1 | 2236 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| COX5A | 2267 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| COX7A2 | 2288 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| CRHR1 | 2357 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| CTSD | 2529 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 34168259 |
| CYCS | 19986 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| DDOST | 2728 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| DDX17 | 2740 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| DDX21 | 2744 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| DDX5 | 2746 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| DLST | 2911 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| EEF1A1 | 3189 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| EEF1A1P5 | 3200 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| EEF1B2 | 3208 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| EEF1D | 3211 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| EEF2 | 3214 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34168259 |
| EIF1AY | 3252 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| EIF3G | 3274 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| EIF4A1 | 3282 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| EIF4A2 | 3284 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| EIF4H | 12741 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| EIF5A | 3300 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| EIF6 | 6159 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ERAP1 | 18173 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| ERO1A | 13280 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| ETFA | 3481 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| ETFB | 3482 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| FABP5 | 3560 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| FAM3C | 18664 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| FARSB | 17800 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| FAU | 3597 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| FTH1 | 3976 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| FUBP1 | 4004 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| FUCA1 | 4006 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| GANAB | 4138 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| GDA | 4212 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| GLO1 | 4323 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| GLRX3 | 15987 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| GLUD1 | 4335 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| GOT1 | 4432 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| GSR | 4623 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| GSTP1 | 4638 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 34168259 |
| H1-0 | 4714 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| HADHA | 4801 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| HEXA | 4878 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| HEXB | 4879 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| HLA-DRA | 4947 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| HLA-DRB1 | 4948 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| HM13 | 16435 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| HNRNPA2B1 | 5033 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| HP1BP3 | 24973 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| HSD17B4 | 5213 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| HSP90AB1 | 5258 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0074 | 34168259 |
| HSP90B1 | 12028 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| HSPA8 | 5241 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0085 | 34168259 |
| HSPE1 | 5269 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 34168259 |
| IDH1 | 5382 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| IPO5 | 6402 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ITGAV | 6150 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| ITGB4 | 6158 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0074 | 34168259 |
| KRT10 | 6413 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| KRT2 | 6439 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| LGALS3BP | 6564 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| LIPA | 6617 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| LXN | 13347 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 34168259 |
| MATR3 | 6912 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| MDH1 | 6970 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 34168259 |
| MDH2 | 6971 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| MIF | 7097 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| MSN | 7373 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| MT-CO2 | 7421 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| MVP | 7531 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| NANS | 19237 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| NCL | 7667 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| NOLC1 | 15608 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| NUCKS1 | 29923 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| OPA1 | 8140 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| PAFAH1B2 | 8575 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| PCNA | 8729 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| PDHA1 | 8806 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| PDIA3 | 4606 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| PDIA6 | 30168 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| PEBP1 | 8630 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| PHB | 8912 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| PHB2 | 30306 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| PIR | 30048 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| PLBD1 | 26215 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| PLPBP | 9457 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| PPA2 | 28883 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| PRDX2 | 9353 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 34168259 |
| PRDX3 | 9354 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| PRDX5 | 9355 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| PRMT1 | 5187 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| PSAP | 9498 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| PSMA5 | 9534 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| PSMB10 | 9538 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| PSMB9 | 9546 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| PSMC5 | 9552 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| PSME1 | 9568 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| RAB2B | 20246 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| RACK1 | 4399 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| RANBP1 | 9847 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL10A | 10299 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL13 | 10303 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| RPL13A | 10304 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34168259 |
| RPL14 | 10305 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL15 | 10306 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL17 | 10307 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL18 | 10310 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL19 | 10312 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| RPL22 | 10315 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL23 | 10316 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| RPL23A | 10317 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| RPL26L1 | 17050 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| RPL3 | 10332 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL31 | 10334 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL32 | 10336 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL35 | 10344 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| RPL35A | 10345 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL4 | 10353 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| RPL6 | 10362 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| RPL7A | 10364 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL8 | 10368 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPL9 | 10369 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| RPLP0 | 10371 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| RPLP2 | 10377 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPN1 | 10381 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| RPN2 | 10382 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| RPS12 | 10385 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| RPS14 | 10387 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPS16 | 10396 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| RPS19 | 10402 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPS23 | 10410 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| RPS25 | 10413 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| RPS26 | 10414 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPS26P11 | 31817 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| RPS28 | 10418 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPS3 | 10420 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| RPS3A | 10421 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| RPS6 | 10429 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RPS7 | 10440 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| RPS8 | 10441 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| RPS9 | 10442 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| RPSA | 6502 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34168259 |
| S100A4 | 10494 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 34168259 |
| S100A6 | 10496 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 34168259 |
| S100P | 10504 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0106 | 34168259 |
| SF3B1 | 10768 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| SFPQ | 10774 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| SLC25A3 | 10989 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| SNCG | 11141 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| SOD1 | 11179 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| SOD2 | 11180 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0064 | 34168259 |
| SQSTM1 | 11280 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| SRP14 | 11299 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| SRSF7 | 10789 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| SSR1 | 11323 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| STOML2 | 14559 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| SUB1 | 19985 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| SYPL1 | 11507 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| TAF15 | 11547 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| TECR | 4551 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| TMED10 | 16998 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| TMEM33 | 25541 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| TOMM40 | 18001 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| TOP1 | 11986 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| TRA2B | 10781 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| TTLL1 | 1312 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| TUBA1B | 18809 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| TUBB | 20778 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| UBA1 | 12469 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| VDAC1 | 12669 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| VDAC3 | 12674 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| XRCC5 | 12833 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| YBX1 | 8014 | HTM | Pancreatic Cancer | Ductal Adenocarcinoma | MIA-PaCa-44 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |